Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The UK SmPCs for semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), as well as their EMA European Public Assessment Reports (EPARs), document well-characterised GI side effect profiles that include nausea, vomiting, diarrhoea, constipation, and dyspepsia
"This is crucial, given the strong link between MASH and cardiovascular, metabolic, and renal conditions, where semaglutide has already shown established health benefits." Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, essentially acting like the natural GLP-1 hormone to help regulate key metabolic processes including reducing appetite and lowering blood sugar
All three of these meds Lower blood glucose levels Promote glucose excretion through urine Offer potential kidney-related benefits May support cardiovascular health in appropriate patients, and Use once-daily dosing The differences between these meds are often smaller than patients expect
Why Everyone Starts at 2.5 mg Tirzepatide is a dual GIP/GLP-1 receptor agonist, and its a potent one
